Janus Kinase (JAK) Inhibitors in Dermatology: An Update and Critical Review

Janus kinase inhibitors have significantly advanced the treatment of complex immune-mediated skin diseases, particularly atopic dermatitis and alopecia areata, with strong evidence supporting their efficacy and acceptable short- to medium-term safety. They also show promise for vitiligo and chronic hand eczema. However, their use requires careful clinical judgment due to potential safety concerns, including acne, herpes zoster, and other mild infections, as well as the need for individualized risk assessments. Overall, these inhibitors offer a transformative approach in dermatology, but long-term safety monitoring is essential.